Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder where misfolded alpha-synuclein-enriched aggregates called Lewy bodies are central in pathogenesis. No neuroprotective or disease-modifying treatments are currently available. Parkinson’s disease is considered a multifactorial disease and evid...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/11/5606 |
| _version_ | 1797532668204679168 |
|---|---|
| author | Johan Wallin Per Svenningsson |
| author_facet | Johan Wallin Per Svenningsson |
| author_sort | Johan Wallin |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is a neurodegenerative disorder where misfolded alpha-synuclein-enriched aggregates called Lewy bodies are central in pathogenesis. No neuroprotective or disease-modifying treatments are currently available. Parkinson’s disease is considered a multifactorial disease and evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. The immune changes occur centrally, involving microglia and astrocytes but also peripherally with changes to the innate and adaptive immune system. Here, we review current understanding of different components of the PD immune response with a particular emphasis on the leukotriene pathway. We will also describe evidence of montelukast, a leukotriene receptor antagonist, as a possible anti-inflammatory treatment for PD. |
| first_indexed | 2024-03-10T11:03:35Z |
| format | Article |
| id | doaj.art-845960057d5340038f2aa36797bd8054 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T11:03:35Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-845960057d5340038f2aa36797bd80542023-11-21T21:21:02ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-05-012211560610.3390/ijms22115606Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s DiseaseJohan Wallin0Per Svenningsson1Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, SwedenLaboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, SwedenParkinson’s disease (PD) is a neurodegenerative disorder where misfolded alpha-synuclein-enriched aggregates called Lewy bodies are central in pathogenesis. No neuroprotective or disease-modifying treatments are currently available. Parkinson’s disease is considered a multifactorial disease and evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. The immune changes occur centrally, involving microglia and astrocytes but also peripherally with changes to the innate and adaptive immune system. Here, we review current understanding of different components of the PD immune response with a particular emphasis on the leukotriene pathway. We will also describe evidence of montelukast, a leukotriene receptor antagonist, as a possible anti-inflammatory treatment for PD.https://www.mdpi.com/1422-0067/22/11/5606montelukastalpha-synucleinleukotrienemicroglianeuroinflammationParkinson’s disease |
| spellingShingle | Johan Wallin Per Svenningsson Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease International Journal of Molecular Sciences montelukast alpha-synuclein leukotriene microglia neuroinflammation Parkinson’s disease |
| title | Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease |
| title_full | Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease |
| title_fullStr | Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease |
| title_full_unstemmed | Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease |
| title_short | Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease |
| title_sort | potential effects of leukotriene receptor antagonist montelukast in treatment of neuroinflammation in parkinson s disease |
| topic | montelukast alpha-synuclein leukotriene microglia neuroinflammation Parkinson’s disease |
| url | https://www.mdpi.com/1422-0067/22/11/5606 |
| work_keys_str_mv | AT johanwallin potentialeffectsofleukotrienereceptorantagonistmontelukastintreatmentofneuroinflammationinparkinsonsdisease AT persvenningsson potentialeffectsofleukotrienereceptorantagonistmontelukastintreatmentofneuroinflammationinparkinsonsdisease |